215 related articles for article (PubMed ID: 25028506)
1. A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.
Lee O; Page K; Ivancic D; Helenowski I; Parini V; Sullivan ME; Margenthaler JA; Chatterton RT; Jovanovic B; Dunn BK; Heckman-Stoddard BM; Foster K; Muzzio M; Shklovskaya J; Skripkauskas S; Kulesza P; Green D; Hansen NM; Bethke KP; Jeruss JS; Bergan R; Khan SA
Clin Cancer Res; 2014 Jul; 20(14):3672-82. PubMed ID: 25028506
[TBL] [Abstract][Full Text] [Related]
2. Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial.
Khan SA; Mi X; Xu Y; Blanco LZ; Akasha AM; Pilewskie M; Degnim AC; AlHilli Z; Amin AL; Hwang ES; Guenther JM; Kocherginsky M; Benante K; Zhang S; Helland T; Hustad SS; Gursel DB; Mellgren G; Dimond E; Perloff M; Heckman-Stoddard BM; Lee O
JAMA Surg; 2023 Dec; 158(12):1265-1273. PubMed ID: 37870954
[TBL] [Abstract][Full Text] [Related]
3. Review: Patient-controlled transdermal 4-hydroxytamoxifen (4-OHT) vs. oral tamoxifen: A systematic review and meta analysis.
Sundralingam U; Khan TM; Elendran S; Muniyandy S; Palanisamy UD
Pak J Pharm Sci; 2019 May; 32(3):1121-1128. PubMed ID: 31278729
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
[TBL] [Abstract][Full Text] [Related]
5. Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation.
Lee O; Ivancic D; Allu S; Shidfar A; Kenney K; Helenowski I; Sullivan ME; Muzzio M; Scholtens D; Chatterton RT; Bethke KP; Hansen NM; Khan SA
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1235-46. PubMed ID: 26560487
[TBL] [Abstract][Full Text] [Related]
6. Novel routes for administering chemoprevention: local transdermal therapy to the breasts.
Lee O; Khan SA
Semin Oncol; 2016 Feb; 43(1):107-115. PubMed ID: 26970129
[TBL] [Abstract][Full Text] [Related]
7. Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast.
Lazzeroni M; Puntoni M; Provinciali N; Webber TB; Briata IM; D'Amico M; Giuliano S; Siri G; Cagnacci S; DeCensi A
Breast; 2019 Nov; 48 Suppl 1():S39-S43. PubMed ID: 31839158
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen Initiation After Ductal Carcinoma In Situ.
Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
[TBL] [Abstract][Full Text] [Related]
9. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
10. Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.
Guerrieri-Gonzaga A; Sestak I; Lazzeroni M; Serrano D; Rotmensz N; Cazzaniga M; Varricchio C; Pruneri G; Leonardi MC; Orecchia R; Galimberti V; Bonanni B; DeCensi A
Int J Cancer; 2016 Nov; 139(9):2127-34. PubMed ID: 27381855
[TBL] [Abstract][Full Text] [Related]
11. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
DeCensi A; Puntoni M; Guerrieri-Gonzaga A; Caviglia S; Avino F; Cortesi L; Taverniti C; Pacquola MG; Falcini F; Gulisano M; Digennaro M; Cariello A; Cagossi K; Pinotti G; Lazzeroni M; Serrano D; Branchi D; Campora S; Petrera M; Buttiron Webber T; Boni L; Bonanni B
J Clin Oncol; 2019 Jul; 37(19):1629-1637. PubMed ID: 30973790
[TBL] [Abstract][Full Text] [Related]
12. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
[TBL] [Abstract][Full Text] [Related]
14. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
[TBL] [Abstract][Full Text] [Related]
15. Postoperative tamoxifen for ductal carcinoma in situ.
Staley H; McCallum I; Bruce J
Cochrane Database Syst Rev; 2012 Oct; 10():CD007847. PubMed ID: 23076938
[TBL] [Abstract][Full Text] [Related]
16. Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Sestak I; Smith SG; Howell A; Forbes JF; Cuzick J
Ann Oncol; 2018 Feb; 29(2):504-509. PubMed ID: 29126161
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
Wapnir IL; Dignam JJ; Fisher B; Mamounas EP; Anderson SJ; Julian TB; Land SR; Margolese RG; Swain SM; Costantino JP; Wolmark N
J Natl Cancer Inst; 2011 Mar; 103(6):478-88. PubMed ID: 21398619
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Emu Oil Transfersomes for Local Transdermal Delivery of 4-OH Tamoxifen in the Treatment of Breast Cancer.
Sundralingam U; Chakravarthi S; Radhakrishnan AK; Muniyandy S; Palanisamy UD
Pharmaceutics; 2020 Aug; 12(9):. PubMed ID: 32854385
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
Harper-Wynne CL; Sacks NP; Shenton K; MacNeill FA; Sauven P; Laidlaw IJ; Rayter Z; Miall S; Howes A; Salter J; Hills MJ; Lowe FM; A'Hern R; Nasiri N; Doody D; Iqbal J; Dowsett M
J Clin Oncol; 2002 Feb; 20(4):1026-35. PubMed ID: 11844826
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
Fisher B; Dignam J; Wolmark N; Wickerham DL; Fisher ER; Mamounas E; Smith R; Begovic M; Dimitrov NV; Margolese RG; Kardinal CG; Kavanah MT; Fehrenbacher L; Oishi RH
Lancet; 1999 Jun; 353(9169):1993-2000. PubMed ID: 10376613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]